Named Bioactive Compounds · Compound
Sophoraflavanone G (Flavanone)
Moderate Evidenceflavonoid3 PubMed Studies
Hermetica Superfood Encyclopedia
Sophoraflavanone G is a flavanone compound extracted from Sophora species that exhibits potent anti-cancer and anti-inflammatory activities. This bioactive flavonoid works by suppressing inflammatory mediators and demonstrating cytotoxic effects against multiple cancer cell lines.
Sophoraflavanone G is a prenylated flavanone compound with the molecular formula C₂₅H₂₈O₆, appearing as a yellowish crystalline solid. It is primarily extracted from plants in the Sophora genus, particularly Sophora flavescens, Sophora pachycarpa, and Sophora exigua, which naturally release it as a volatile phytoncide for antimicrobial protection. The compound is commercially available at ≥95-99% purity from chemical suppliers.
No human clinical trials, randomized controlled trials (RCTs), or meta-analyses have been conducted on Sophoraflavanone G. All available research is limited to preclinical studies, including in vitro cell culture experiments and animal models, particularly examining anti-cancer, anti-inflammatory, and antimicrobial properties.
No clinically studied dosage ranges are available for Sophoraflavanone G due to the absence of human trials. Consult a healthcare provider before starting any new supplement.
Sophoraflavanone G is a prenylated flavanone (molecular formula: C₂₅H₂₈O₆; molecular weight: ~424.49 g/mol) and is not a nutritional food source but rather a bioactive phytochemical isolated primarily from the roots of Sophora flavescens (Kushen) and other Sophora species. Key profile details: • **Chemical class:** Prenylated flavanone (2S-configuration typical); bears a lavandulyl-type prenyl group at the C-8 position of the A-ring and hydroxyl groups at C-5, C-7, C-2', and C-4' positions. • **Typical concentrations in source plant material:** Reported at approximately 0.01–0.5% (w/w) of dried root extract of Sophora flavescens, varying with extraction method and plant origin. • **Bioactive co-occurring compounds in source matrices:** Often co-extracted with kurarinone, kushenol series flavonoids, matrine and oxymatrine (alkaloids), sophoraflavanone B and D, and other prenylated flavonoids. • **No macronutrient contribution:** As an isolated phytochemical, it provides negligible calories, protein, fat, carbohydrate, or dietary fiber. • **No significant vitamin or mineral content** as a purified compound. • **Bioavailability notes:** Oral bioavailability is expected to be low-to-moderate due to its lipophilic prenylated structure (LogP estimated ~4.5–5.0), which enhances membrane interaction but limits aqueous solubility. The prenyl group may improve cellular uptake relative to non-prenylated flavanones. Likely subject to extensive Phase I (CYP450-mediated oxidation) and Phase II (glucuronidation, sulfation) hepatic metabolism. Intestinal efflux via P-glycoprotein may further reduce systemic availability. No human pharmacokinetic studies are currently published; animal studies suggest rapid absorption with a short plasma half-life. Lipid-based delivery systems or nanoformulations may improve bioavailability. • **Solubility:** Poorly soluble in water; soluble in DMSO, ethanol, and methanol. • **Stability:** Sensitive to light and oxidative degradation; storage recommended at −20°C in amber vials under inert atmosphere.
Sophoraflavanone G exerts its anti-inflammatory effects by suppressing key inflammatory mediators and inhibiting eicosanoid-generating enzymes including cyclooxygenase and lipoxygenase pathways. The compound demonstrates anti-cancer activity through induction of apoptosis and cell cycle arrest in malignant cells. It also enhances antibacterial activity by disrupting bacterial cell wall integrity and increasing membrane permeability.
Current research on Sophoraflavanone G is limited to preclinical in vitro and animal studies. Laboratory studies show IC50 values ranging from 10-50 μM against various cancer cell lines including HL-60 leukemia, MCF-7 breast cancer, and A549 lung cancer cells. Anti-inflammatory studies demonstrate significant reduction in nitric oxide production and pro-inflammatory cytokine release in macrophage cell cultures. Human clinical trials have not yet been conducted to establish therapeutic efficacy or optimal dosing protocols.
Safety data for Sophoraflavanone G in humans is currently unavailable due to lack of clinical studies. Potential interactions with cytochrome P450 enzymes may affect metabolism of concurrent medications, though specific drug interactions have not been documented. Pregnancy and breastfeeding safety has not been established. Individuals with existing medical conditions or taking medications should consult healthcare providers before use.
